Peak oxygen consumption as a predictor of death in patients with heart failure receiving β-blockers

被引:212
作者
O'Neill, JO [1 ]
Young, JB [1 ]
Pothier, CE [1 ]
Lauer, MS [1 ]
机构
[1] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA
关键词
heart failure; exercise; adrenergic beta-antagonists; prognosis; ventricular dysfunction; left;
D O I
10.1161/01.CIR.0000164270.72123.18
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background-Peak oxygen uptake (peak Vo(2)) is a strong predictor of mortality and is commonly used in the evaluation of patients for cardiac transplantation. beta-Blockers reduce mortality in patients with heart failure, without influencing peak Vo(2), raising the possibility that peak Vo(2) is no longer suitable as an indicator of prognosis in these patients. Methods and Results-We analyzed prospectively gathered data on 2105 patients referred for cardiopulmonary testing for all-cause mortality and for occurrence of death or transplantation. Patients receiving beta-blockers were younger, more likely to have coronary disease, and had a greater mean ejection fraction but had a similar peak Vo(2). There were 555 deaths (26%) and 194 (9%) transplants during a median follow-up of 3.5 years. Peak Vo(2) was a predictor of mortality irrespective of beta-blocker use; a decrease of 1 mL - kg(-1) - min(-1) resulted in an adjusted hazard ratio (HR) of 1.13 (95% CI 1.09 to 1.17, P < 0.0001) in patients not receiving beta-blockers and 1.27 (95% CI 1.18 to 1.36, P < 0.0001) in patients receiving beta-blockers. Similar findings were noted when considering death or transplantation as an end point. beta-Blocker use was associated with better outcomes until peak Vo(2) values became very low (approximate to 10 mL - kg(-1) - min(-1)), at which level survival rates were equally poor. Conclusion-Peak Vo(2) is a determinant of survival in patients in heart failure even in the setting of beta-blockade. Because of improved survival in patients treated with beta-blockers, the cut point value of 14 mg - kg(-1) - min(-1) for referral for cardiac transplantation in these patients requires reevaluation, and a lower cut point may be more appropriate.
引用
收藏
页码:2313 / 2318
页数:6
相关论文
共 32 条
[1]
A NEW METHOD FOR DETECTING ANAEROBIC THRESHOLD BY GAS-EXCHANGE [J].
BEAVER, WL ;
WASSERMAN, K ;
WHIPP, BJ .
JOURNAL OF APPLIED PHYSIOLOGY, 1986, 60 (06) :2020-2027
[2]
COHN JN, 1993, CIRCULATION, V87, P5
[3]
SELECTION AND TREATMENT OF CANDIDATES FOR HEART-TRANSPLANTATION - A STATEMENT FOR HEALTH-PROFESSIONALS FROM THE COMMITTEE ON HEART-FAILURE AND CARDIAC TRANSPLANTATION OF THE COUNCIL ON CLINICAL CARDIOLOGY, AMERICAN-HEART-ASSOCIATION [J].
COSTANZO, MR ;
AUGUSTINE, S ;
BOURGE, R ;
BRISTOW, M ;
OCONNELL, JB ;
DRISCOLL, D ;
ROSE, E .
CIRCULATION, 1995, 92 (12) :3593-3612
[4]
ASCERTAINMENT OF VITAL STATUS THROUGH THE NATIONAL DEATH INDEX AND THE SOCIAL-SECURITY-ADMINISTRATION [J].
CURB, JD ;
FORD, CE ;
PRESSEL, S ;
PALMER, M ;
BABCOCK, C ;
HAWKINS, CM .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 121 (05) :754-766
[5]
FISHER L, 1983, CIRCULATION, V68, P951
[6]
MAXIMAL EXERCISE TOLERANCE AS A THERAPEUTIC END-POINT IN HEART-FAILURE - ARE WE RELYING ON THE RIGHT MEASURE [J].
FRANCIS, GS ;
RECTOR, TS .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (04) :304-306
[7]
FRANCIS GS, 1994, J HEART LUNG TRANSPL, V13, pS113
[8]
Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart [J].
Gilbert, EM ;
Abraham, WT ;
Olsen, S ;
Hattler, B ;
White, M ;
Mealy, P ;
Larrabee, P ;
Bristow, MR .
CIRCULATION, 1996, 94 (11) :2817-2825
[9]
Dead is dead - Artificial definitions are no substitute [J].
Gottlieb, SS .
LANCET, 1997, 349 (9053) :662-663
[10]
Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure -: a substudy to the MERIT-HF trial [J].
Gullestad, L ;
Manhenke, C ;
Aarsland, T ;
Skårdal, R ;
Fagertun, H ;
Wikstrand, J ;
Kjekshus, J .
EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (04) :463-468